

August 5, 2025

Q1FY26 Result Update

☑ Change in Estimates | ■ Target | ■ Reco

Change in Estimates

	Current		Previous	
	FY26E	FY27E	FY26E	FY27E
Rating	BUY		BUY	
Target Price	1,720		1,720	
Sales (Rs. m)	14,575	17,774	14,484	17,672
% Chng.	0.6	0.6		
EBITDA (Rs. m)	3,592	4,238	3,609	4,250
% Chng.	(0.5)	(0.3)		
EPS (Rs.)	32.7	38.4	34.5	39.3
% Chng.	(5.2)	(2.2)		

Key Financials - Consolidated

Y/e Mar	FY24	FY25	FY26E	FY27E
Sales (Rs. m)	10,598	12,615	14,575	17,774
EBITDA (Rs. m)	2,285	2,965	3,592	4,238
Margin (%)	21.6	23.5	24.6	23.8
PAT (Rs. m)	1,630	1,935	2,144	2,520
EPS (Rs.)	24.9	29.5	32.7	38.4
Gr. (%)	92.7	18.7	10.8	17.5
DPS (Rs.)	0.9	1.0	1.2	1.2
Yield (%)	0.1	0.1	0.1	0.1
RoE (%)	21.2	15.3	14.7	15.0
RoCE (%)	18.6	16.8	15.3	16.0
EV/Sales (x)	8.7	7.4	6.4	5.3
EV/EBITDA (x)	40.3	31.5	26.1	22.1
PE (x)	58.4	49.2	44.4	37.7
P/BV (x)	8.1	7.0	6.1	5.3

Key Data

JUPE.BO | JLHL IN

52-W High / Low	Rs.1,770 / Rs.1,250
Sensex / Nifty	81,019 / 24,723
Market Cap	Rs.95bn / \$ 1,085m
Shares Outstanding	66m
3M Avg. Daily Value	Rs.61.91m

Shareholding Pattern (%)

Promoter's	40.91
Foreign	9.77
Domestic Institution	15.82
Public & Others	33.50
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(3.7)	(11.9)	7.6
Relative	(0.8)	(14.5)	7.6

Param Desai

paramdesai@plindia.com | 91-22-66322259

Sanketa Kohale

sanketakhale@plindia.com | 91-22-66322426

In-line quarter aided by higher ARPOB

Quick Pointers:

- ARPOB grew by 13% YoY aided by better case and payor mix
- On track for beds expansion to 2500

JLHL's Q1 consolidated EBITDA grew by 20% YoY (flat QoQ) to Rs781mn, in line with our estimates, aided by higher ARPOB. Its operational efficiency has been strong in the competitive markets of MMR. The company reported revenue/EBITDA CAGR of 20%/25% over FY22-25. Given its expansion plans, scale-up in occupancy and improving margins, growth momentum is expected to sustain over the medium term. We believe strategic greenfield expansions in densely populated micro-markets of western regions will drive sustainable growth. Our FY26E and FY27E EBITDA broadly remain unchanged, but PAT has been reduced by ~2-5% given the higher depreciation and interest charges. Overall, we see 20%/14% CAGR in EBITDA/PAT over FY25-27E with healthy return ratios of ~16%. Maintain 'BUY' rating with a TP of Rs1,720/share, valuing at 26x EV/EBITDA based on FY27E EBITDA.

- In-line EBITDA; PAT impacted due to higher depreciation and tax:** JLHL reported EBITDA of Rs781mn, up 20% YoY. Margins were flat YoY (down 150 bps QoQ) to 22.5%. PAT de-growth was at 2% YoY due to higher depreciation and interest charges partly offset by higher other income. Higher depreciation and interest charges were driven by capitalization of newly added beds in Q4 and debt taken for bed expansion plan; respectively.
- Strong ARPOB; YoY occupancy declines due to new bed addition:** JLHL reported revenue growth of 21% YoY to Rs3.5bn, vs our estimates of Rs3.3bn. Revenue beat was due to inclusion of Rs 66mn of pharmacy revenues in Q1, following a change in reporting. This product mix shift led to a 230bps YoY decline in gross margins. ARPOB continues to improve by 13% YoY to Rs67.3k per day, driven by inflation-linked price hikes across all units and case mix optimization, particularly at the Indore hospital. Average occupancy decreased by 380bps YoY to 60.1%, due to the addition of 78 beds at Indore unit in Q4. QoQ Occupancy improved by 120 bps. IP and OP volumes increased by 5% and 12% YoY, respectively.
- Key con-call takeaways:** The company continues to be on track to achieve its initial target of 2,500 beds across 6 hospitals in Western India in the next 3-4 years.
- Bed expansion and capex –** Total 3 greenfield projects are in the portfolio. These include 500 beds at **Dombivli**, construction work is progressing well and ~250 beds are expected to be operational in Q1FY27. Incurred Rs 2bn of capex so far and guided for another capex of Rs 2bn to be incurred in few months with breakeven guidance within 12 months. Mgmt plans to commercialize second phase once the unit achieves 60% occupancy with capex requirement of Rs. 1bn. The second hospital in **Bibwewadi, Pune**, construction is planned to commence in

Q3FY26. In the case of the **Mira-Bhayandar hospital**, regulatory processes are underway for recently acquired 2 acres of land to build a 300-bed unit.

- **Capex Phasing:** Typically spread as 15% in Year 1, 25% in Year 2, and 60% in Year 3 (excluding land cost).
- **Net debt** – JLHL's net cash stood at Rs2.75bn as of Q1FY26. JLHL has total debt of Rs 3.25bn.
- **Thane unit** - Maintained near-mature occupancy (~mid-70%) in Q1. Environmental approval for adding an extra floor at Thane is stalled due to a Supreme Court-linked issue.
- **Pune Unit:** Improved occupancy YoY; case mix largely matured with limited room for improvement.
- **Indore unit** - Ramp-up continues with increasing occupancy and ongoing case mix optimization. Newly added 78 beds (from Q4FY25) seeing traction.
- **Higher depreciation** - Depreciation increased by over Rs 100mn YoY in Q1FY26, driven by capex in new census beds, OTs, and biomedical equipment including surgical robots, MRIs, and cath labs. While QoQ increased in depreciation led by new beds added at Indore unit in Q4.
- **Guidance for FY26E** - Expect continued organic growth led by Indore and Pune. Thane remains stable. EBITDA margins expected to sustain; however, PAT margins to compress due to increased depreciation and finance cost from prior capex.
- **Renewable Energy Capex** - Commissioned 1.2 MW solar plant at Indore (~Rs 50mn outlay, guided for Rs 10mn annual savings). Currently, Mgmt is in process of evaluating 3 MW solar in Maharashtra to support future units.
- Contribution from the insurance business increased to 56.3% in 1QFY26 vs 52.8% in Q1FY25.

Exhibit 1: Q1FY26 Result Overview (Rs mn) – In-line EBITDA, PAT impacted by higher depreciation charges

Y/e March	1QFY26	1QFY25	YoY gr. (%)	Q1FY26E	% Var.	4QFY25	QoQ gr. (%)	FY26E	FY25	YoY gr. (%)
Net Sales	3,476	2,871	21.1	3,303	5.2	3,267	6.4	14,575	12,615	14.8
COGS	684	502	36.1	587	16.5	611	11.8	2,620	2,302	13.1
<i>% of Net Sales</i>	<i>19.7</i>	<i>17.5</i>		<i>17.8</i>		<i>18.7</i>		<i>18.0</i>	<i>18.2</i>	
Employee Cost	594	513	15.9	579	2.6	538	10.5	2,424	2,145	13.0
<i>% of Net Sales</i>	<i>17.1</i>	<i>17.9</i>		<i>17.5</i>		<i>16.5</i>		<i>16.6</i>	<i>17.0</i>	
Other Expenses	1,417	1,218	16.4	1,361	4.1	1,335	6.1	5,939	5,203	12.4
<i>% of Net Sales</i>	<i>40.8</i>	<i>42.4</i>		<i>41.2</i>		<i>40.9</i>		<i>40.7</i>	<i>41.2</i>	
Total	2,695	2,233	20.7	2,527	6.6	2,485	8.5	10,983	9,650	12.7
EBITDA	781	639	22.4	776	0.7	783	(0.2)	3,592	2,965	21.7
<i>Margins (%)</i>	<i>22.5</i>	<i>22.2</i>		<i>23.5</i>		<i>24.0</i>		<i>24.6</i>	<i>23.5</i>	
Other Income	129	84	53.7	80	60.8	70	83.1	441	287	26.9
Interest	83	11	666.5	55	50.1	56	48.2	310	106	127.4
Depreciation	212	110	92.8	175	21.2	176	20.4	865	570	23.0
PBT	615	601	2.3	626	(1.7)	621	(0.9)	2,858	2,577	17.7
Tax	177	155	13.6	156	12.8	172	2.5	715	642	18.1
<i>Tax rate %</i>	<i>28.7</i>	<i>25.8</i>		<i>25.0</i>		<i>27.7</i>		<i>25.0</i>	<i>24.9</i>	
PAT	439	446	(1.6)	469	(6.5)	449	(2.2)	2,144	1,935	17.5
Extraordinary items	-	-		-		-		-	-	
Minority Interest	-	-		-		-		-	-	
Reported PAT	438	446	(1.7)	469	(6.6)	449	(2.3)	2,144	1,935	17.5


Source: Company, PL

Exhibit 2: IP and OP volumes up by 5% and 12% YoY, respectively

Particulars (Rs m)	FY24	H1FY25	9MFY25	FY25	Q1FY26
ARPOB (Rs per day)	54,871	57,700	59,100	60,600	67,300
Occupancy (%)	63.8	67.2	66.7	65.3	60.1
IP (#)	49,100	27,200	40,200	52,900	13,300
OP (#)	8,31,200	458,800	687,300	9,26,400	2,45,800
ALOS	3.93	3.85	3.88	3.89	3.78


Source: Company, PL

Exhibit 3: EBITDA margins were flat YoY




Source: Company, PL

Exhibit 4: Price hike & improved case mix aided 13% YoY ARPOB growth




Source: Company, PL

Exhibit 5: Occupancy declined by 380 bps YoY due to new beds addition




Source: Company, PL

Exhibit 6: Inpatient volumes grow 5% YoY in Q1FY26



Source: Company, PL

Exhibit 7: Outpatient volumes grow 12% YoY in Q1FY26



Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Net Revenues	10,598	12,615	14,575	17,774
YoY gr. (%)	18.7	19.0	15.5	21.9
Cost of Goods Sold	1,895	2,302	2,620	3,199
Gross Profit	8,703	10,313	11,955	14,574
Margin (%)	82.1	81.8	82.0	82.0
Employee Cost	1,899	2,145	2,424	2,836
Other Expenses	4,519	5,203	5,939	7,500
EBITDA	2,285	2,965	3,592	4,238
YoY gr. (%)	13.5	29.8	21.1	18.0
Margin (%)	21.6	23.5	24.6	23.8
Depreciation and Amortization	424	570	865	1,014
EBIT	1,861	2,395	2,727	3,224
Margin (%)	17.6	19.0	18.7	18.1
Net Interest	263	106	310	293
Other Income	220	287	441	428
Profit Before Tax	1,818	2,577	2,858	3,359
Margin (%)	17.2	20.4	19.6	18.9
Total Tax	188	642	715	840
Effective tax rate (%)	10.3	24.9	25.0	25.0
Profit after tax	1,630	1,935	2,144	2,520
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	1,630	1,935	2,144	2,520
YoY gr. (%)	123.5	18.7	10.8	17.5
Margin (%)	15.4	15.3	14.7	14.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,630	1,935	2,144	2,520
YoY gr. (%)	123.5	18.7	10.8	17.5
Margin (%)	15.4	15.3	14.7	14.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	1,630	1,935	2,144	2,520
Equity Shares O/s (m)	66	66	66	66
EPS (Rs)	24.9	29.5	32.7	38.4

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Non-Current Assets				
Gross Block	10,037	12,840	15,701	19,223
Tangibles	10,015	12,794	15,656	19,178
Intangibles	21	46	46	46
Acc: Dep / Amortization	2,860	3,066	3,931	4,945
Tangibles	2,860	3,066	3,931	4,945
Intangibles	-	-	-	-
Net fixed assets	7,176	9,774	11,771	14,279
Tangibles	7,155	9,729	11,725	14,233
Intangibles	21	46	46	46
Capital Work In Progress	740	1,851	1,851	1,851
Goodwill	-	-	-	-
Non-Current Investments	959	1,691	1,691	1,691
Net Deferred tax assets	(68)	(72)	(72)	(72)
Other Non-Current Assets	9	5	5	5
Current Assets				
Investments	-	-	-	-
Inventories	213	241	276	337
Trade receivables	572	419	592	722
Cash & Bank Balance	3,013	4,887	4,596	4,539
Other Current Assets	125	177	195	215
Total Assets	12,813	19,049	20,980	23,643
Equity				
Equity Share Capital	656	656	656	656
Other Equity	11,035	12,907	14,974	17,418
Total Network	11,690	13,562	15,630	18,073
Non-Current Liabilities				
Long Term borrowings	-	3,217	3,217	3,217
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	-	40	40	40
Trade payables	622	1,029	868	1,060
Other current liabilities	435	454	479	506
Total Equity & Liabilities	12,813	19,049	20,980	23,642

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
PBT	1,954	2,577	2,858	3,359
Add. Depreciation	424	570	865	1,014
Add. Interest	263	106	310	293
Less Financial Other Income	220	287	441	428
Add. Other	(190)	(544)	-	-
Op. profit before WC changes	2,451	2,708	4,033	4,667
Net Changes-WC	(809)	499	(362)	8
Direct tax	(497)	(674)	(715)	(840)
Net cash from Op. activities	1,145	2,533	2,957	3,835
Capital expenditures	(852)	(3,203)	(2,862)	(3,522)
Interest / Dividend Income	236	198	0	0
Others	(143)	919	-	-
Net Cash from Invst. activities	(759)	(2,086)	(2,862)	(3,522)
Issue of share cap. / premium	6,326	-	-	-
Debt changes	(4,725)	3,257	-	-
Dividend paid	(57)	(66)	(76)	(76)
Interest paid	(263)	(106)	(310)	(293)
Others	(1)	(1,658)	0	0
Net cash from Fin. activities	1,281	1,428	(386)	(369)
Net change in cash	1,667	1,875	(291)	(57)
Free Cash Flow	292	(674)	95	312

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY24	FY25	FY26E	FY27E
Per Share(Rs)				
EPS	24.9	29.5	32.7	38.4
CEPS	31.3	38.2	45.9	53.9
BVPS	178.3	206.9	238.4	275.7
FCF	4.5	(10.3)	1.4	4.8
DPS	0.9	1.0	1.2	1.2
Return Ratio(%)				
RoCE	18.6	16.8	15.3	16.0
ROIC	19.0	16.9	16.6	16.9
RoE	21.2	15.3	14.7	15.0
Balance Sheet				
Net Debt : Equity (x)	(0.3)	(0.1)	(0.1)	(0.1)
Net Working Capital (Days)	6	(11)	-	-
Valuation(x)				
PER	58.4	49.2	44.4	37.7
P/B	8.1	7.0	6.1	5.3
P/CEPS	46.3	38.0	31.6	26.9
EV/EBITDA	40.3	31.5	26.1	22.1
EV/Sales	8.7	7.4	6.4	5.3
Dividend Yield (%)	0.1	0.1	0.1	0.1

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q2FY25	Q3FY25	Q4FY25	Q1FY26
Net Revenue	3,226	3,206	3,267	3,476
YoY gr. (%)	22.6	17.6	12.5	20.5
Raw Material Expenses	600	588	611	684
Gross Profit	2,626	2,618	2,656	2,793
Margin (%)	81.4	81.7	81.3	80.3
EBITDA	750	750	783	781
YoY gr. (%)	22.9	21.3	25.7	19.6
Margin (%)	23.2	23.4	24.0	22.5
Depreciation / Depletion	144	140	176	212
EBIT	606	610	606	569
Margin (%)	18.8	19.0	18.6	16.4
Net Interest	11	28	56	83
Other Income	94	83	70	129
Profit before Tax	689	666	621	615
Margin (%)	21.4	20.8	19.0	17.7
Total Tax	174	140	172	177
Effective tax rate (%)	25.2	21.1	27.7	28.7
Profit after Tax	515	525	449	439
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	515	525	449	438
YoY gr. (%)	52.9	20.3	(0.9)	(1.7)
Margin (%)	16.0	16.4	13.7	12.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	515	525	449	438
YoY gr. (%)	49.5	19.9	4.4	(1.7)
Margin (%)	16.0	16.4	13.7	12.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	515	525	449	438
Avg. Shares O/s (m)	-	-	-	-
EPS (Rs)	7.9	8.0	6.8	6.7

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	08-Jul-25	BUY	1,720	1,531
2	13-May-25	BUY	1,720	1,422
3	08-Apr-25	BUY	1,750	1,480
4	10-Feb-25	BUY	1,750	1,607
5	08-Jan-25	BUY	1,660	1,565
6	12-Nov-24	BUY	1,660	1,482
7	07-Oct-24	BUY	1,475	1,432
8	12-Aug-24	BUY	1,475	1,315

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	8,350	7,616
2	Aster DM Healthcare	BUY	700	605
3	Aurobindo Pharma	BUY	1,440	1,185
4	Cipla	BUY	1,730	1,533
5	Divi's Laboratories	Accumulate	6,800	6,889
6	Dr. Reddy's Laboratories	Reduce	1,270	1,247
7	Eris Lifesciences	BUY	1,740	1,734
8	Fortis Healthcare	BUY	785	806
9	HealthCare Global Enterprises	BUY	620	560
10	Indoco Remedies	Hold	325	322
11	Ipca Laboratories	Accumulate	1,525	1,456
12	J.B. Chemicals & Pharmaceuticals	BUY	2,030	1,778
13	Jupiter Life Line Hospitals	BUY	1,720	1,531
14	Krishna Institute of Medical Sciences	BUY	725	695
15	Lupin	BUY	2,400	1,979
16	Max Healthcare Institute	BUY	1,300	1,300
17	Narayana Hrudayalaya	BUY	1,950	1,990
18	Rainbow Children's Medicare	BUY	1,725	1,541
19	Sun Pharmaceutical Industries	BUY	1,875	1,707
20	Sunteck Realty	BUY	650	427
21	Torrent Pharmaceuticals	Accumulate	4,000	3,623
22	Zydus Lifesciences	Accumulate	970	999

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com